R. Abratt

发表

R. Abratt, 1979 .

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.

W. Bezwoda, L. Goedhals, G. Falkson, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Letter in response to paper by Abratt et al., Cancer Chemother Pharmacol (1992) 30: 495

S. Senan, R. Abratt, 1993, Cancer Chemotherapy and Pharmacology.

Resection of a solitary brain metastasis in a patient with small cell lung cancer--long-term survival.

P. Willcox, R. Abratt, M. de Groot, 1995, European journal of cancer.

Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.

F. Shepherd, R. Ramlau, M. Krzakowski, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

Chih-Hsin Yang, F. de Marinis, J. Wolf, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Does the tumor microenvironment influence radiation-induced apoptosis?

M. Renan, R. Abratt, A. Hunter, 2006, Apoptosis.

Impact of adjuvant chemotherapy (CT) on survival and local-control in non-small cell lung cancer (NSCLC): Results of the international adjuvant lung cancer trial (IALT)

R. Arriagada, J. Pignon, R. Gralla, 2004 .

Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer.

M. Dimopoulos, F. Selvaggi, S. Oudard, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel as neo-adjuvant therapy for radically treatable stage III non-small cell lung cancer: early results of an international phase III study.

K. Mattson, R. Abratt, I. Avril, 2001, Lung cancer.

The effect of irradiation on lung function and perfusion in patients with lung cancer.

P. Willcox, R. Abratt, 1995, International journal of radiation oncology, biology, physics.

10-year update on chemotherapy for non-small cell lung cancer.

R. Abratt, G. Hart, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer.

S. Clarke, M. Millward, S. Ackland, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

1086 A phase II study of gemcitabine with cisplatin in patients with non-small cell lung cancer

W. Bezwoda, L. Goedhals, R. Abratt, 1995 .

A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.

I. Bodrogi, A. Stenzl, J. Horti, 2009, Cancer biotherapy & radiopharmaceuticals.

31 Differential efficacy and toxicity profiles of 4 different schedules of gemcitabine and cisplatin combination in non-small cell lung cancer (NSCLC)

L. Crinò, Mark R. Green, B. Nguyen, 1997 .

Epidemiologie des Pleuramesothelioms

R. Abratt, N. White, 2005 .

Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer

C. Martín, B. Lund, H. Cortés-Funes, 1997, Anti-cancer drugs.

Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer.

W. Bezwoda, L. Goedhals, R. Abratt, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma.

P. Willcox, R. Abratt, H. Goodman, 1991, European journal of cancer.

Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.

W. Bezwoda, L. Goedhals, R. Abratt, 1997, Seminars in oncology.

When the tumor is not the target: a title whose time is up?

R. Abratt, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical research in developing countries--ethical dilemmas.

R. Abratt, 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Adding paclitaxel to supportive care seems to improve survival and delay time to progression in people with non-small cell lung cancer

R. Abratt, 2000 .

A "good death" revisited in the context of doctor-patient relationships.

R. Abratt, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neutron therapy and increased late complication rates.

R. Abratt, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Randomized phase II studies and their ethics.

R. Stephens, N. Enas, R. Abratt, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study.

G. T. ten Velde, K. Mattson, R. Abratt, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Commentary on “Novel Doublets in Extensive-Stage Small-Cell Lung Cancer: A Randomized Phase II Study of Topotecan Plus Cisplatin or Paclitaxel (CALGB 9430)”

R. Abratt, 2002 .

Statement on withholding and withdrawing life-sustaining therapy.

D. Dent, D. Benatar, J. Degenaar, 1994, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Changes in lung function and perfusion after irradiation in patients with lung cancer.

P. Willcox, R. Abratt, 1994, Lung cancer.

perfusion after lung cancer

R. Abratt, Paul A. Willcoxb, 1994 .

Testicular cancer and cryptorchidism.

R. Abratt, V. Reddi, L. Sarembock, 1992, British journal of urology.

Adjuvant chemotherapy for stage I non-seminomatous testicular cancer.

B. Reddi, R. Abratt, R. Barnes, 1994, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Choriocarcinoma and transitional cell carcinoma of the bladder--a case report and review of the clinical evolution of disease in reported cases.

R. Abratt, A. Pontin, C. Temple-Camp, 1989, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Activity of a short course of interferon α for metastatic renal cell carcinoma — a phase-2 study

R. Abratt, A. Pontin, H. S. Ball, 1993, Cancer Immunology, Immunotherapy.

Lung cancer management in limited resource settings: guidelines for appropriate good care.

B. Jeremic, R. Stephens, F. Macbeth, 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The use of hyperbaric oxygen as an adjunct in the treatment of radionecrosis.

R. Abratt, E. Mills, 1978, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer.

F. Shepherd, L. Crinò, A. Sandler, 2000, Lung cancer.

Who will guard the guards? Medical leadership and conflict of interest in South African healthcare.

R. Abratt, 2016, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Angiosarcoma of the superior vena cava

R. Abratt, C. Uys, M. Williams, 1983, Cancer.

Synchronous contralateral adrenal metastasis from renal cell carcinoma: a 7 year survival following resection.

D. Dent, R. Abratt, R. Barnes, 1995, The Australian and New Zealand journal of surgery.

Long-term changes in pulmonary function tests after definitive irradiation for lung cancer.

R. Abratt, 2004, International journal of radiation oncology, biology, physics.

Part I: Cancer in Indigenous Africans--burden, distribution, and trends.

Lara Stein, Freddy Sitas, D. Parkin, 2008, The Lancet. Oncology.

Part II: Cancer in Indigenous Africans--causes and control.

D. Parkin, F. Sitas, H. Wabinga, 2008, The Lancet. Oncology.

Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.

G. Peters, F. Shepherd, L. Crinò, 1998, Seminars in oncology.

Epidemiology of mesothelioma--a South African perspective.

R. Abratt, D. Vorobiof, N. White, 2005, Lung cancer.

Asbestos and mesothelioma in South Africa.

Neil White, R. Abratt, Raymond P Abratt, 2004, Lung cancer.

Malignant pleural mesothelioma: a phase II trial with docetaxel.

M. Chasen, B. Rapoport, R. Abratt, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of invasive thymoma at Groote Schuur Hospital, Cape Town.

P. Willcox, R. Abratt, M. de Groot, 1991, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Oral topotecan demonstrates clinical activity in relapsed non-small cell lung cancer. Results from an open-label, phase III study (387) comparing oral topotecan to intravenous docetaxel

F. Shepherd, R. Ramlau, M. Krzakowski, 2005 .

The treatment of bilateral ulcerated lymph node metastases from carcinoma of the penis. A case report

R. Abratt, 1984 .

Radical irradiation of localized inoperable lung cancer with concurrent chemotherapy and misonidazole: a phase I/II study.

P. Willcox, R. Abratt, R. Hewitson, 1987, European journal of cancer & clinical oncology.

Current chemotherapy of advanced non-small cell lung cancer

R. Abratt, 1995, Anti-cancer drugs.

Rationing and decision making.

R. Abratt, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pulmonary complications of radiation therapy.

G. Silvestri, P. Willcox, R. Abratt, 2004, Clinics in chest medicine.

Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer.

F. Shepherd, U. Gatzemeier, H. Anderson, 1997, Seminars in oncology.

Concurrent radiation and weekly cisplatin for non-small-cell lung cancer — a phase I/II study

P. Willcox, R. Abratt, D. Salton, 2004, Cancer Chemotherapy and Pharmacology.

Lung toxicity following chest irradiation in patients with lung cancer.

R. Abratt, G. Morgan, 2002, Lung cancer.

Palliative radiation for stage 3 non-small cell lung cancer--a prospective study of two moderately high dose regimens.

R. Abratt, L. Shepherd, D. Salton, 1995, Lung cancer.

Assessment of quality of life by clinicians--experience of a practical method in lung cancer patients.

R. Abratt, G. Viljoen, 1995, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Predictive value of perfusion lung scans on post irradiation pulmonary function.

R. Abratt, 1993, International journal of radiation oncology, biology, physics.

Lung cancer in patients with borderline lung functions--zonal lung perfusion scans at presentation and lung function after high dose irradiation.

J. Smith, P. Willcox, R. Abratt, 1990, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Scientific fraud and international research.

P. Ruff, L. Goedhals, R. Abratt, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost considerations in determining the affordability of adjuvant trastuzumab in breast cancer.

R. Abratt, 2016, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

The cancer burden in Africa.

R. Abratt, D. Vorobiof, 2007, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Combined modality therapy of lung cancer and lung tolerance.

R. Abratt, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Representation on International Scientific Committees.

R. Abratt, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

A prospective randomised study in limited disease small cell carcinoma--doxorubicin and vincristine plus either cyclophosphamide or etoposide.

P. Willcox, R. Abratt, D. Salton, 1995, European journal of cancer.

Modeling tumor and treated lung volume influences in the irradiation of non-small-cell lung cancer patients.

R. Abratt, 2001, International journal of radiation oncology, biology, physics.

Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer.

U. Gatzemeier, E. Tan, P. Zatloukal, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Radical irradiation and misonidazole in the treatment of T2 grade III and T3 bladder cancer.

M. Williams, J. Green, R. Abratt, 1983, International journal of radiation oncology, biology, physics.

Treatment of carcinoma of the anal canal at Groote Schuur Hospital.

R. Abratt, P. Goldberg, A. Hunter, 2012, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Hypofractionated irradiation for non-small cell lung cancer.

J. Bogart, R. Abratt, A. Hunter, 2002, Lung cancer.

Review article Hypofractionated irradiation for non-small cell lung cancer

J. Bogart, R. Abratt, A. Hunter, 2002 .

Phase II Trial of Gemcitabine-Carboplatin-Paclitaxel as Neoadjuvant Chemotherapy for Operable Non-small Cell Lung Cancer

Chun-Ming Tsai, T. Mok, M. Lehnert, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effective treatment of patients with T1 grade III bladder cancer by external beam irradiation.

R. Abratt, R. Tucker, D. Barnes, 1984, International journal of radiation oncology, biology, physics.

Salvage cystectomy after radical irradiation for bladder cancer-prognostic factors and complications.

J. Wilson, R. Abratt, R. Barnes, 1993, British journal of urology.

Neo-adjuvant chemotherapy and radical irradiation for locally advanced bladder cancer--a phase 2 study.

R. Abratt, R. Barnes, A. Pontin, 1994, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.

M. Riggi, M. Reck, P. Cornes, 2009, Lung cancer.

Branch trial 3 ( GLOB 3 ) : final results of a randomised multinational phase III study alternating oral and i . v . vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer

U. Gatzemeier, E. Tan, P. Zatloukal, 2009 .

Dose-effect relationships for functional local injury after lung irradiation.

R. Abratt, 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Vinorelbine (NVB)-carboplatin (CBDCA) vs non-platinum doublets in inoperable non-small cell lung cancer (NSCLC) patients (pts)-final results of the Glob 2 phase III with patient benefit analysis.

E. Tan, A. Szczesna, O. Bertetto, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Use of Venous Access Devices in Patients Younger than 21 years with Cancer to Improve the Ease of Administration of Intravenous Therapies

R. Abratt, 2013 .

Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer.

M. Krzakowski, U. Gatzemeier, E. Tan, 2005, Lung cancer.

Adult Wilms' tumor cisplatin and etoposide for relapse after adjuvant chemotherapy

R. Kaschula, R. Abratt, H. Du Michael Preez, 1990, Cancer.

Pretreatment minimal staging and prognostic factors for non-small cell lung cancer.

P. Rocmans, V. Ninane, R. Stahel, 1997, Lung cancer.

Efficacy and safety of gemcitabine in non small cell lung cancer (NSCLC)

W. Bezwoda, L. Goedhals, G. Falkson, 1993 .

Etoposide combination therapy for small cell carcinoma of the lung

P. Willcox, R. Abratt, R. Hewitson, 2004, Cancer Chemotherapy and Pharmacology.

Stereotactic Ablative Body Radiotherapy for Metastases Needs Better Evidence.

F. Macbeth, R. Abratt, 2021, JAMA oncology.

Early results of an international phase III study evaluating Taxotere as neo-adjuvant therapy for radically-treatable stage III NSCLC

K. Mattson, V. Cour-Chabernaud, R. Abratt, 2000 .

Radical irradiation and misonidazole for T2 grade III and T3 bladder cancer: 2 year follow-up.

R. Abratt, R. Tucker, D. Barnes, 1984, International journal of radiation oncology, biology, physics.

Bioavailability and pharmacokinetic characteristics of dexniguldipine-HCl, a new anticancer drug.

W. Bezwoda, L. Goedhals, W. Wurst, 1995, International journal of clinical pharmacology and therapeutics.

Overt hypoadrenalism is uncommon in patients with stage 3 and 4 bronchogenic carcinoma.

S. Isaacs, S. Soule, R. Abratt, 2003, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA – N 2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy †

Ronald, Ramalingam, Igor, 2015 .